Bio-Path Holdings to Present at the 2021 American Association for Cancer Research Annual Meeting

Rhea-AI Summary

Bio-Path Holdings (NASDAQ: BPTH) announced a virtual poster presentation at the 2021 American Association for Cancer Research (AACR) Annual Meeting from April 10-15 and May 17-21, 2021. Dr. Maria Gagliardi will present pre-clinical studies of BP1002 combined with decitabine, targeting venetoclax-resistant cancer cells.

Presentation Details:
Date: April 10, 2021
Time: 8:30 am ET
Session: Biological Therapeutic Agents
Abstract Number: 939
Title: Efficacy of BP1002 with decitabine in resistant cells.

HOUSTON, March 11, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming virtual poster presentation at the 2021 American Association for Cancer Research (AACR) Annual Meeting, taking place April 10-15 and May 17-21, 2021.

Dr. Maria Gagliardi, a Research Scientist at Bio-Path Holdings, will discuss pre-clinical studies of BP1002 (liposomal Bcl-2 antisense) in combination with decitabine as a potential treatment against venetoclax-resistant cells.

Details for the virtual poster presentation are as follows:

Date: April 10, 2021
Presentation Time: 8:30 am Eastern Time
Session: Biological Therapeutic Agents
Abstract Number: 939
Title: The combination of liposomal Bcl-2 antisense oligonucleotide (BP1002) with decitabine is efficacious in venetoclax-resistant cells

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company developing DNAbilize^®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for the treatment of blood cancers and prexigebersen-A, a drug product modification of prexigebersen, is under consideration by the FDA to commence Phase 1 studies in solid tumors. This is followed by BP1002, targeting the Bcl-2 protein, where it is being evaluated in a Phase 1 study in advanced lymphoma and chronic lymphocytic leukemia patients.

For more information, please visit the Company's website at http://www.biopathholdings.com.

Contact Information:

Investors

Will O’Connor
Stern Investor Relations, Inc.
212-362-1200
will@sternir.com

Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369

FAQ

What is the significance of BPTH's virtual poster presentation at AACR 2021?

BPTH's virtual poster presentation at AACR 2021 showcases pre-clinical studies of BP1002, which may lead to new treatment options for venetoclax-resistant cancer patients.

When is the AACR Annual Meeting where BPTH is presenting?

The AACR Annual Meeting takes place from April 10-15 and May 17-21, 2021.

Who will present the findings on BP1002 at the AACR 2021?

Dr. Maria Gagliardi, a Research Scientist at Bio-Path Holdings, will present the findings on BP1002.

What is BP1002, and how is it being used in the study presented by BPTH?

BP1002 is a liposomal Bcl-2 antisense oligonucleotide being studied in combination with decitabine to treat venetoclax-resistant cancer cells.

What are the details of the presentation regarding BP1002 at AACR 2021?

The presentation is scheduled for April 10, 2021, at 8:30 am Eastern Time during the Biological Therapeutic Agents session, with abstract number 939.